311 – 320 of 459
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2003
-
Mark
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen
(
- Contribution to journal › Article
-
Mark
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer
(
- Contribution to journal › Article
-
Mark
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
(
- Contribution to journal › Article
-
Mark
Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)
(
- Contribution to journal › Article
-
Mark
Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation.
(
- Contribution to journal › Article
-
Mark
Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening
(
- Contribution to journal › Article
-
Mark
Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
(
- Contribution to journal › Article
-
Mark
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable
(
- Contribution to journal › Article
-
Mark
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
(
- Contribution to journal › Article
-
Mark
Expression and immunolocalisation of neutral endopeptidase in prostate cancer
(
- Contribution to journal › Article